Effect of Intranasal Insulin on Cognitive Processes and Appetite

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study investigates the effect of intranasal insulin on cognitive processes (behavioural and neural) in healthy lean and obese female adults. All subjects will receive a single-dose of intranasal insulin and/or placebo (on different days) before participating in several cognitive tasks.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Birmingham
• Collaborator: Queen Elizabeth Hospital NHS Foundation Trust
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Healthy female subjects

• Age 18-65 years at start of the study

• Body Mass Index (BMI) between 18 and 25 kg/m2 for the lean group and between 30 and 40 kg/m2 for the obese group

• Right-handedness (including left-handers could bias the results because of the laterality of brain functions)

• Ability to give informed consent

• Fluent English speaking

• Willingness to be informed about chance findings of pathology

Exclusion Criteria:

• Subjects who have a non-removable metal object in or at their body, such as, for example: Heart pace-maker, artificial heart valve, metal prosthesis, implants or splinters, non-removable dental braces

• Tattoos, that are older than 15 years

• Claustrophobia

• Limited temperature perception and/or increased sensitivity to warming of the body

• Pathological hearing ability or an increased sensitivity to loud noises

• Lack of ability to give informed consent

• Operation less than three months ago

• Simultaneous participation in other studies that involve drugs intake or blood spending

• Acute illness or infection during the last 4 weeks

• Cardiovascular disorders (e.g., hypertrophic cardiomyopathy, long QT syndrome)

• Moderate or severe head injury

• Eating disorders

• No metabolic (e.g. metabolic disorder, diabetes, insulin resistance), psychological (e.g. depression) or neurological (e.g. epilepsy, headache disorder, multiple sclerosis, traumatic brain injuries) diseases or medication in relation to these diseases.

• Intake of any medication that can interfere with the drug or measurements.

• Current weight loss regimens, or more then 5kg weight loss in the last 3 months

• Smoking

• Current pregnancy or breastfeeding

• Current or past history of drug or alcohol dependency - alcohol consumption exceeding 12 units a week

• Food allergies (e.g. peanut allergy lactose and gluten intolerance) or vegetarian/vegan diet

• Disliking the study lunch